INTRODUCTION {#s1}
============

Mutations in the *ABCA4* gene (STGD1, MIM \#248200) ([@MCS002733ZERC2]) are the most frequent cause of Mendelian inherited recessive retinal dystrophies. Phenotypes of ABCA4 disease range from late-onset mild cases of central atrophy to very early-onset, RP-like, panretinal degeneration ([@MCS002733ZERC10]; [@MCS002733ZERC17]; [@MCS002733ZERC18]; [@MCS002733ZERC23]; [@MCS002733ZERC15]; [@MCS002733ZERC8]; [@MCS002733ZERC26]). Phenotypic variability is caused by extensive *ABCA4* disease-associated genetic variation, where more than 1000 definitely or possibly disease-causing variants have been determined in the coding sequences and splice sites of the *ABCA4* gene ([@MCS002733ZERC9]) (J Zernant, and R Allikmets, unpubl. data). Recently, the understanding of disease-causing genetic variation in *ABCA4* has substantially improved as a result of two major advances. First, many noncoding disease-associated *ABCA4* alleles have been identified and proven pathogenic, mostly by affecting splicing ([@MCS002733ZERC30]; [@MCS002733ZERC31]; [@MCS002733ZERC3]; [@MCS002733ZERC4]; [@MCS002733ZERC21], [@MCS002733ZERC22]; [@MCS002733ZERC1]). Second, we recently determined that some *ABCA4* variants, which had been considered benign because of high minor allele frequency (MAF) in the general population, are in fact very mild conditional alleles, which result in disease expression only when in *trans* with a deleterious mutation, thereby called "extreme hypomorphs" ([@MCS002733ZERC32]). Altogether, although these findings have increased the fraction of definitively diagnosed cases of ABCA4 disease substantially, 10%--15% of all STGD1 cases remain with only one proven disease-causing mutation.

It has been also demonstrated that large copy-number variants (CNVs) that elude detection by sequencing are exceptionally rare in the *ABCA4* locus ([@MCS002733ZERC15]). Whole-exome sequencing (WES) of patients with phenotypes compatible with STGD1, but in which no *ABCA4* mutations had been identified after complete sequencing of the *ABCA4* locus (i.e., phenocopies), has uncovered causal genes in ∼70% of cases, including known retinal disease--associated genes (*CRB1*, *CRX*, etc.) ([@MCS002733ZERC27]; [@MCS002733ZERC29]) and new genes (*RAB28*, *RDH11*) ([@MCS002733ZERC28]; [@MCS002733ZERC19]). Therefore, the remaining "missing" alleles in monoallelic cases likely reside in the noncoding sequences of *ABCA4* and are waiting to be assigned pathogenicity. In this study, we investigated three deep intronic variants ([Table 1](#MCS002733ZERTB1){ref-type="table"}) for pathogenicity by an integrated analysis of clinical and genetic data in a large, familial cohort of patients with STGD1.

###### 

*ABCA4* deep intronic variants investigated in this study

  Gene      Chromosome        Variant      HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect on splicing   dbSNP         Genotype
  --------- ------------ ----------------- -------------------- ------------------------ -------------- ------------------------------ ------------- -------------------
  *ABCA4*   1:94496509     c.4253+43G\>A   G                    Noncoding                Substitution   None                           rs61754045    100% heterozygous
  *ABCA4*   1:94484082    c.5196+1056A\>G  A                    Noncoding                Substitution   Activates cryptic donor site   rs886044749   100% heterozygous
  *ABCA4*   1:94471747    c.6006-609T\>A   T                    Noncoding                Substitution   None                           rs575968112   100% heterozygous

RESULTS {#s2}
=======

Determining Pathogenicity of Three Noncoding *ABCA4* Variants {#s2a}
-------------------------------------------------------------

We had previously identified and described an intronic variant, c.4253+43G\>A (rs61754045) in intron 28 of the *ABCA4* gene ([@MCS002733ZERC30]). At that time we noted that the variant was statistically significantly (*P* = 0.0003) more often found in STGD1 patients and also two times more frequently in cases with age-related macular degeneration than in matched general population controls (individuals \>60 yr of age with no retinal pathology) ([@MCS002733ZERC30]). We had suggested that the c.4253+43G\>A variant was a good candidate for a disease-associated allele, but we were not able to make an unequivocal call of pathogenicity.

According to the updated data, the variant is present in 29/1155 STGD1 cases, almost exclusively in those with only one definite *ABCA4* mutation (23/160, 14.38%; MAF = 0.072; [Table 2](#MCS002733ZERTB2){ref-type="table"}), compared to MAF = 0.006 in non-Finnish European control cohort (gnomAD; [Table 3](#MCS002733ZERTB3){ref-type="table"}). It was also present in 0.41% (3/725) of biallelic patients and in 1.1% (3/270) of cases with no other disease-causing *ABCA4* alleles ([Table 2](#MCS002733ZERTB2){ref-type="table"}). Therefore, the c.4253+43G\>A variant is substantially enriched in STGD1 cases, specifically in those with one known pathogenic allele (*P* \< 1 × 10^−7^; OR = 12.87 95% CI \[8.37;19.79\]). Family members were available for segregation analyses in ∼30% of cases, which always resulted in phasing the c.4253+43G\>A allele in *trans* with the known *ABCA4* mutation. All variants in *trans* from the c.4253+43G\>A variant are severe, mostly confirmed loss-of-function alleles ([Table 2](#MCS002733ZERTB2){ref-type="table"}), the situation exactly matching our recent observation for a frequent missense *ABCA4* allele, c.5603A\>T (p.Asn1868Ile; rs1801466) ([@MCS002733ZERC32]).

###### 

STGD1 patients with deep intronic disease-associated *ABCA4* variants

  Patient   Disease-associated *ABCA4* variants in *trans*              Pathogenicity class   Deep-intronic disease-associated *ABCA4* variants
  --------- ----------------------------------------------------------- --------------------- ---------------------------------------------------
  1         c.161G\>A (p.Cys54Tyr)                                      PS3                   c.\[4253+43G\>A;6006-609T\>A\]
  2         c.161G\>A (p.Cys54Tyr)                                      PS3                   c.\[4253+43G\>A;6006-609T\>A\]
  3         c.247_250dup (p.Ser84Thrfs\*15)                             PVS1                  c.4253+43G\>A^a^
  4         c.768G\>T (p.Leu257Valfs\*17)                               PVS1                  c.4253+43G\>A^a^
  5         c.768G\>T (p.Leu257Valfs\*17)                               PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  6         c.\[1622T\>C;3113C\>T\] (p.\[Leu541Pro;Ala1038Val\])        PS3                   c.\[4253+43G\>A;6006-609T\>A\]
  7         c.1819G\>A (p.Gly607Arg)                                    PS4                   c.4253+43G\>A^a^
  8         c.1819G\>A (p.Gly607Arg)                                    PS4                   c.4253+43G\>A
  9         c.1988G\>A (p.Trp663\*)                                     PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  10        c.3470T\>G (p.Leu1157\*)                                    PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  11        c.3814-2A\>G (p.?)                                          PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  12        c.3898C\>T (p.Arg1300\*)                                    PVS1                  c.4253+43G\>A^a^
  13        c.4248C\>A (p.Phe1416Leu)                                   PP3                   c.4253+43G\>A
  14        c.4539+1G\>T (p.?)                                          PVS1                  c.4253+43G\>A^a^
  15        c.4539+1729G\>T (p.?)                                       PP3                   c.\[4253+43G\>A;6006-609T\>A\]
  16        c.4918C\>T (p.Arg1640Trp)                                   PS3                   c.\[4253+43G\>A;6006-609T\>A\]
  17        c.5312+2T\>G (p.?)                                          PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  18        c.5461-10T\>C (p.Thr1821Valfs\*13, p.Thr1821Aspfs\*6)       PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  19        c.5461-10T\>C (p.Thr1821Valfs\*13, p.Thr1821Aspfs\*6)       PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  20        c.5461-10T\>C (p.Thr1821Valfs\*13, p.Thr1821Aspfs\*6)       PVS1                  c.\[4253+43G\>A;6006-609T\>A\]
  21        c.5461-10T\>C (p.Thr1821Valfs\*13, p.Thr1821Aspfs\*6)       PVS1                  c.4253+43G\>A
  22        c.5461-10T\>C (p.Thr1821Valfs\*13, p.Thr1821Aspfs\*6)       PVS1                  c.4253+43G\>A
  23        c.5914G\>A (p.Gly1972Arg)                                   PM2                   c.4253+43G\>A^a^
  24        c.\[70C\>T(;)2041C\>T\] (p.\[Arg24Cys(;)Arg681\*\])         PP3, PVS1             c.4253+43G\>A^a^
  25        c.\[4139C\>T(;)5308T\>G\] (p.\[Pro1380Leu(;)Tyr1770Asp\])   PS3, PM2              c.\[4253+43G\>A;6006-609T\>A\]
  26        c.6543_6578del (p.Leu2182_Phe2193del) homozygote            PVS1                  c.4253+43G\>A
  27        ND                                                                                c.\[4253+43G\>A;6006-609T\>A\]
  28        ND                                                                                c.4253+43G\>A
  29        ND                                                                                c.4253+43G\>A
  30        c.1726G\>C (p.Asp576His)                                    PS4                   c.5196+1056A\>G
  31        c.3056C\>T (p.Thr1019Met)                                   PS4                   c.5196+1056A\>G
  32        c.3413T\>A (p.Leu1138His)                                   PM2                   c.5196+1056A\>G
  33        c.5882G\>A (p.Gly1961Glu)                                   PS3                   c.5196+1056A\>G
  34        c.5882G\>A (p.Gly1961Glu)                                   PS3                   c.5196+1056A\>G

Nucleotide positions and protein translation correspond to CCDS747.1 and NP_000341.2, respectively. Nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide 1.

ND, not detected.

^a^Not screened for c.6006-609T\>A.

###### 

Population frequency and in silico analysis of deep intronic *ABCA4* variants

  Chr 1 position (hg19)   *ABCA4* deep intronic variant   MAF in non-Finnish European controls   MAF in STGD1 cohort (*n*)   MAF in STGD1 with one *ABCA4* mutation (n)   CADD score   Predicted effect on splicing   Associated with STGD1
  ----------------------- ------------------------------- -------------------------------------- --------------------------- -------------------------------------------- ------------ ------------------------------ -----------------------
  94496509                c.4253+43G\>A                   0.006                                  0.013 (1155)                0.069 (160)                                  6.491        No                             Yes
  94484082                c.5196+1056A\>G                 0                                      0.003 (834)                 N/A                                          1.067        Yes                            Yes
  94471747                c.6006-609T\>A                  0.0047                                 0.009 (834)                 0.049 (132)                                  1.848        No                             No

Specifically, 26 unrelated patients harbor the c.4253+43G\>A allele in *trans* from another *ABCA4* mutation ([Table 2](#MCS002733ZERTB2){ref-type="table"}). Of these, 16 patients carry *ABCA4* variants, which are either LOF/null by definition (i.e., nonsense, frameshift, ±1 or 2 in splice sites) or as shown in functional studies, including c.5461-10T\>C (p.Thr1821Valfs\*13, p.\|Thr1821Aspfs\*6) ([@MCS002733ZERC21]). Of the missense alleles, several (e.g., c.\[1622T\>C;3113C\>T\] (p.\[Leu541Pro;Ala1038Val\]) ([@MCS002733ZERC33]), c.161G\>A (p.Cys54Tyr), c.4139C\>T (p.Pro1380Leu) ([@MCS002733ZERC25]), and c.4918C\>T (p.Arg1640Trp) ([@MCS002733ZERC24])) have direct functional proof. The c.5914G\>A (p.Gly1972Arg) variant has been identified in a STGD1 patient *in trans* from other hypomorphic allele ([@MCS002733ZERC32]). Therefore, the direct functional/clinical proof is currently vague for only three variants, c.1819G\>A (p.Gly607Arg), c.4248C\>A (p.Phe1416Leu), and c.4539+1729G\>T (p.?). Altogether, these data allowed us to assign pathogenicity to the c.4253+43G\>A variant; it is the second reported extremely hypomorphic *ABCA4* allele, and first in noncoding sequences (i.e., it is causal only when in *trans* with a loss-of-function mutation).

Another deep intronic variant we had previously described ([@MCS002733ZERC31]) and suggested as "possibly associated with the disease," c.6006-609T\>A (rs575968112), was seen in 15/834 (1.8%; MAF = 0.009) screened cases (MAF = 0.0047 in non-Finnish European control cohort, [Table 3](#MCS002733ZERTB3){ref-type="table"}). Upon further analysis we determined that it forms a complex allele c.\[4253+43G\>A;6006-609T\>A\] (i.e., occurs on the same allele) in about 70% of cases in our cohort ([Table 2](#MCS002733ZERTB2){ref-type="table"}). The c.6006-609T\>A variant is always allelic with the c.4253+43G\>A variant and has not been detected alone. According to the gnomAD database, the c.4253+43G\>A variant is 1.2--2 times more frequent than c.6006-609T\>A in every population except for Finnish Europeans, where the frequency of both variants is the same. Both variants are absent in East Asian population. Because both alleles, the c.4253+43G\>A variant alone and the complex allele c.\[4253+43G\>A;6006-609T\>A\], are equally pathogenic based on genetic and clinical analyses, it is very likely that the hypomorphic c.4253+43G\>A allele is pathogenic and the c.6006-609T\>A is not, because the c.6006-609T\>A allele does not add severity to the complex allele. Neither of these two variants are predicted to have any effect on splicing, whether on existing cryptic splice sites or on creating new sites, although c.4253+43G\>A alters a splice silencer (ESS) and creates a splicing enhancer (ESE) SF2/ASF site ([Supplemental Fig. 1A,B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002733/-/DC1)). Thus, an alternative splicing in photoreceptors caused by the c.4253+43G\>A variant is likely. Recently, aberrant splicing caused by other *ABCA4* intronic disease-associated variants, c.5461-10T\>C, c.4539+2001G\>A, and c.4539+2028C\>T, was demonstrated in patient-derived photoreceptor precursor cells (PPCs), whereas no effect on splicing by these variants was predicted in silico ([@MCS002733ZERC21]; [@MCS002733ZERC1]).

The third rare deep intronic variant, c.5196+1056A\>G (rs886044749) ([@MCS002733ZERC5]; [@MCS002733ZERC31]), is found in 5/834 (0.6%) of STGD1 cases ([Tables 2](#MCS002733ZERTB2){ref-type="table"}, [3](#MCS002733ZERTB3){ref-type="table"}). Unlike the c.4253+43G\>A and c.6006-609T\>A variants, the c.5196+1056A\>G variant is predicted to strongly activate a cryptic splice donor. Together with a strong cryptic splice acceptor downstream at c.5196+1318, splicing from these cryptic sites would result in a putative 262-bp pseudoexon inclusion and a frameshift in translation ([Supplemental Fig. 1C](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002733/-/DC1)). The variant is very rare, it is not described in any public databases (gnomAD, 1000 Genomes), and it was found exclusively in patients with one known *ABCA4* mutation. All variants in *trans* from the c.5196+1056A\>G are known disease-associated *ABCA4* alleles ([Table 2](#MCS002733ZERTB2){ref-type="table"}). In contrast to the c.4253+43G\>A and the complex, c.\[4253+43G\>A;6006-609T\>A\] alleles, variants in *trans* from the c.5196+1056A\>G variant do not include obvious loss-of-function alleles. For example, the frequent p.Gly1961Glu pathogenic variant in two families ([Fig. 1](#MCS002733ZERF1){ref-type="fig"}B,C) consistently segregates with milder disease phenotypes similar to those observed in patients harboring p.Asn1868Ile ([@MCS002733ZERC6], [@MCS002733ZERC7]; [@MCS002733ZERC32]). Therefore, the aggregate evidence suggests that the c.5196+1056A\>G variant is a rare, severe, deep intronic disease-associated allele.

![Examples of pedigrees showing the segregation of the deep intronic variants, c.\[4253+ 43G\>A;6006-609T\>A\] and c.5196+1056A\>G, of *ABCA4* in the families of (*A*) Patient 2, (*B*) Patient 33, and (*C*) Patient 31. Black arrowheads indicate the affected index patient in each family.](MCS002733Zer_F1){#MCS002733ZERF1}

According to ENCODE analysis the three deep intronic variants are not located in predicted gene regulatory regions. The Combined Annotation Dependent Depletion (CADD) scores for these variants are also below the predicted pathogenic range of \>20, but variants closer to coding sequences (c.4253+43G\>A and c.6006-609T\>A) score higher for their predicted possible deleterious effect ([Table 3](#MCS002733ZERTB3){ref-type="table"}).

All three deep-intronic nucleotide positions are fully conserved, and adjacent sequences are also relatively conserved in nonhuman primates, suggesting an important functional role for these nucleotides---a crucial additional evidence for determining pathogenicity for a variant. All three alleles segregated with the disease in available families; that is, they were in *trans* from the proband\'s second pathogenic *ABCA4* allele (examples in [Fig. 1](#MCS002733ZERF1){ref-type="fig"}A--C).

Clinical Expression of the Three Noncoding *ABCA4* Variants {#s2b}
-----------------------------------------------------------

Patients harboring the c.4253+43G\>A variant alone or as a complex allele with c.6006-609T\>A were predominantly Caucasian and relatively older in age with most cases presenting to the clinic in the fifth and sixth decade of life (median age at initial examination, 49.0 yr; range, 19--71 yr) ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002733/-/DC1)). Most patients had relatively centralized fixation and visual acuity was correctable to 20/40 or better in at least one eye in 83% of patients. Reported ocular histories were consistent with a more recent or later onset of visual symptoms (median, 40.5 yr). Three patients reported symptomatic onset before the age of 20 yr; however, visual acuity in both eyes at the time was only marginally decreased, correctable between 20/25--20/40. Anterior segment examinations were unremarkable with the exception of mild nuclear sclerosis (NS+1) in a few cases. Dilated funduscopic examinations showed healthy optic discs, intact retinal vasculature, and otherwise normal peripheral retina. The most predominant features on funduscopy were retinal pigment epithelium (RPE) mottling, small patches of atrophy, through which large choroidal vessels were visible, and a reticular arrangement of yellow, pisciform flecks across the macula and mid-periphery ([Fig. 2](#MCS002733ZERF2){ref-type="fig"}A,D). Disease changes were notably absent in the peripapillary region. The presence of dark pigment migration was only noted in the macula of one case (Patient 15), depositing in the foveola and along the temporal edge of the atrophic lesion in the right eye.

![Clinical phenotype of patients harboring the deep intronic c.4253+43G\>A variant of *ABCA4* as a complex allele with c.6006-609T\>A. (*A*) Color fundus photograph and (*B*) 488-nm autofluorescence (488-nm AF) image of the left eye of a 66-yr-old man (Patient 9, with c.1988G\>A (p.Trp663\*) in *trans*) exhibiting mottled atrophy and a distribution of autofluorescent flecks across the paramacular region of the fundus. (*C*) Spectral domain-optical coherence tomography (SD-OCT) revealed complete sparing of the photoreceptor-attributable layers, outer nuclear layer (ONL), external limiting membrane (ELM), ellipsoid zone (EZ), and RPE in the fovea resulting in preserved visual acuity of 20/20. (*D*) Color fundus photograph, (*E*) 488-nm AF image, and (*F*) SD-OCT scan of a 52-yr old woman (Patient 2, with c.161G\>A (p.Cys54Tyr) in *trans*) revealing similar disease changes extending out into the midperiphery. Residual thickness of the foveal RPE layer can be noted, although the visible thinning of the ONL and absence of the ELM and EZ layers resulted in significantly decreased visual acuity (20/200) in this eye. (*G*) Full-field electroretinograms (ffERG) of Patient 2 and Patient 9 revealed relatively normal scotopic, maximal, and photopic and borderline 30-Hz flicker responses in both eyes. Areas delineated by dashed boxes indicate healthy amplitude and implicit time ranges.](MCS002733Zer_F2){#MCS002733ZERF2}

Fundus autofluorescence (AF, 488-nm) abnormalities corresponding to changes observed on funduscopy were evident in all patients ([Fig. 2](#MCS002733ZERF2){ref-type="fig"}B,E). Flecks were generally more hypoautofluorescent within the central macula and comparatively less confluent in the periphery indicating a centrifugal pattern of expansion. Lesions of discrete atrophy were homogenously hypoautofluorescent with uneven but well-demarcated edges. Very few patients demonstrated a complete loss of autofluorescence in the fovea. Remarkably, 83.3% of the cohort presented with structural and functional sparing of the fovea (VA 20/40 or better) in at least one eye at the initial examination---three patients (Patient 6, Patient 8, and Patient 9) exhibited unilateral sparing. SD-OCT through the fovea revealed intermittent disruptions of the reflective outer retinal bands, ELM, EZ, and interdigitation zone (IZ). Regions of discrete atrophy presented as areas of increased signal transmission into the underlying choroid because of the visible disruption of the photoreceptor layers and thinned or absent RPE. SD-OCT revealed visible preservation of all outer retinal bands ([Fig. 2](#MCS002733ZERF2){ref-type="fig"}C, inset) in cases of complete foveal sparing such as Patient 9 (c.\[4253+43G\>A;6006-609T\>A\], p.Cys54Tyr\*). Those with poor central acuity, such as Patient 2 (c.\[4253+43G\>A;6006-609T\>A\], p.Trp663\*) ([Fig. 2](#MCS002733ZERF2){ref-type="fig"}F, inset), were generally found to have ELM--EZ layer disruption but residual RPE reflectivity and thickness in the fovea on SD-OCT.

Virtually all patients for whom data were available had preserved generalized cone and rod function on full-field electroretinogram (ffERG) testing. Marginal decreases in 30-Hz flicker peak amplitudes were measured in five patients at the mean age of 57.6 yr (range, 42 to 71 yr). Representative scotopic, maximal, 30-Hz flicker and photopic waveforms from the right and left eyes of Patient 2 and Patient 7 are presented in [Figure 2](#MCS002733ZERF2){ref-type="fig"}G. Follow-up examinations across periods of 1 to 29 yr revealed little indication of disease progression with respect to observable changes on funduscopy. Most patients also remained functionally stable at subsequent follow-up examinations, although a decrease in visual acuity, greater than two lines of vision, was evident in 25% of the cohort between the third and fifth decades of life. No significant distinctions between the clinical characteristics of patients harboring the c.4253+43G\>A variant alone and patients harboring the c.4253+43G\>A as a complex allele with c.6006-609T\>A were noted.

DISCUSSION {#s3}
==========

Variation in the *ABCA4* gene is extensive, and the complete understanding of genetic causality still remains obscure in at least 20% of all cases. The gene is expressed only in photoreceptors and, possibly, in the RPE, which renders RNA-based functional analyses challenging. This is specifically true for analyses of variants outside of coding regions for which protein-based tests are impossible.

Analyses of intronic variants have been attempted ([@MCS002733ZERC20]; [@MCS002733ZERC5]) with the "illegitimate transcript" or "minigene" strategies to assess the effect of certain variants on splicing. These studies have limitations and the results, although suggestive, cannot be considered unequivocal ([@MCS002733ZERC21]). Most recently, a "midigene" approach was proposed, which is very effective for variants in canonical and noncanonical splice consensus sequences ([@MCS002733ZERC22]). Analysis of variants in deep intronic sequences of *ABCA4*, however, remains a tedious endeavor through iPSC-derived PPC ([@MCS002733ZERC1]). Although the PPC approach is gaining traction, the initial analysis for pathogenicity can be performed in very large, familial cohorts of STGD1 patients by a combination of in silico approaches including the assessment of variant frequencies in STGD1 patients and in the matched general populations, suggestions by predictive software programs, segregation analyses in families, and integration of clinical and genetic analysis. As demonstrated in this and in previous studies ([@MCS002733ZERC31], [@MCS002733ZERC32]), we have been able to assign pathogenicity to several variants in intronic sequences of *ABCA4* by using these strategies prior to direct RNA- or protein-based functional studies. The latter, however, are still needed to determine the specific effect of variants on *ABCA4* RNA and protein and would allow suggesting specific treatment modalities, such as AON-based correction of splicing ([@MCS002733ZERC1]).

The clinical phenotype of patients with the c.4253+43G\>A allele is largely consistent with the described profile of STGD1 patients harboring the recently described hypomorphic c.5603A\>T (p.Asn1868Ile) allele ([@MCS002733ZERC32]). As compared to the more prevalent adolescent-onset form of STGD1, ([@MCS002733ZERC13]; [@MCS002733ZERC26]) patients harboring c.4253+43G\>A or c.5603A\>T (p.Asn1868Ile) progress through milder disease trajectories characterized by the confinement of disease changes to the macula, slower accumulation of flecks, and a significantly later onset of disease symptoms (fifth to sixth decade). The latter is likely a reflection of the enrichment of foveal sparing subphenotype in both the c.4253+43G\>A (83.3%) and c.5603A\>T (p.Asn1868Ile) (84.7%) groups. Several mechanisms for foveal sparing in ABCA4 disease and age-related macular degeneration (AMD) have been proposed, including the protective role of luteal macular pigment, anatomical arrangement, and morphology of foveal cones ([@MCS002733ZERC11]) and the utilization of 11-cis retinol from Muller cells ([@MCS002733ZERC14]). However, our current findings support the hypothesis that slow disease progression is likely a major contributing factor for the functional persistence of cones in the fovea.

In summary, the analysis of three possibly disease-associated *ABCA4* deep intronic variants revealed that two of these, the c.4253+43G\>A and c.5196+1056A\>G variants, are pathogenic, whereas the c.6006-609T\>A variant is not. The c.5196+1056A\>G variant is a highly penetrant, likely severe, allele, whereas the c.4253+43G\>A variant is an "extreme hypomorph," which is clinically expressed only when in *trans* with a loss-of-function *ABCA4* allele. Functional studies involving *ABCA4* RNA obtained from individual patients via iPS cells differentiated into PPCs would be the ultimate proof of specific functional outcome of each allele. However, these analyses are unlikely to change the clinical pathogenicity assessment obtained by integrated clinical and genetic analyses.

METHODS {#s4}
=======

Patients {#s4a}
--------

STGD1 patients were recruited and clinically examined during a 20-yr period in different centers in the United States and in Europe. Ancestry of all patients was assessed from questionnaires and determined to be non-Finnish European. In total, 1155 patients were included in the analyses. Age of onset was defined as the age at which symptoms were first reported. Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study Chart 1 or a Snellen acuity chart. Clinical examination, fundus photography, AF, and SD-OCT (Heidelberg Spectralis HRA+OCT) were performed using standard acquisition protocols following pupil dilation with Tropicamide 1% and Neosynephrine 2%.

Sequencing and Analysis of the *ABCA4* Variants {#s4b}
-----------------------------------------------

Sequencing of the *ABCA4* gene in 1155 patients was performed using 454 Titanium method (Roche) or Illumina TruSeq Custom Amplicon protocol (Illumina). ([@MCS002733ZERC30], [@MCS002733ZERC31]) Sequencing of the entire *ABCA4* locus was performed in 217 patients using the RainDance target enrichment (RainDance Technologies) with Roche 454 sequencing or Illumina TruSeq Custom Amplicon protocol ([@MCS002733ZERC31]). For genotyping of deep intronic variants in patient and control cohorts TaqMan Genotyping technology (Life Technologies) was applied. The variants' segregation with the disease in available families was analyzed by Sanger sequencing.

All variants and their allele frequencies were compared to the 1000 Genomes database ([@MCS002733ZERC12]) and to the gnomAD data set ([@MCS002733ZERC16]) (<http://gnomad.broadinstitute.org>; accessed April 2018). Frequent variants (MAF \> 0.01) were considered nonpathogenic. Rare variants and variants identified with at least two times higher frequency in STGD1 patients than in the general control population were analyzed by a combination of predictive in silico methods and statistical analyses ([@MCS002733ZERC31]). The possible effect of noncoding *ABCA4* variants on splicing was assessed using five different algorithms (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder) via Alamut software (<http://www.interactive-biosoftware.com>). The regulatory potential of the *ABCA4* intronic variants was assessed by comparing their chromosome coordinates against the predicted regulatory regions from two ENCODE data sets: (1) combined DNase I hypersensitivity clusters from 125 cell types ("Digital DNase I Hypersensitivity Clusters in 125 cell types from ENCODE") and (2) ChIP-seq clustered regions for 161 transcription factors in 91 cell types ("Transcription Factor ChIP-seq V4 (161 factors) with Factorbook motifs from ENCODE"). Evolutionary conservation of the variants was noted via UCSC Genome Browser (<http://genome.ucsc.edu>). The CADD algorithm (<http://cadd.gs.washington.edu/score>) was used to estimate combined predicted general deleteriousness of every variant. Combined data from MAF comparisons, predictive programs, determining the variants' segregation with the disease were used to determine pathogenicity for the identified deep intronic variants. Statistical calculations using allele frequencies in cases and controls were performed with a 2 × 2 table. More detailed methods are provided in [Supplement Materials](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002733/-/DC1).
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